Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000179255 | SCV000231475 | uncertain significance | not provided | 2017-10-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000616618 | SCV000820492 | likely benign | X-linked Emery-Dreifuss muscular dystrophy | 2024-11-27 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000179255 | SCV001143862 | likely benign | not provided | 2019-03-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002298506 | SCV002598550 | uncertain significance | not specified | 2022-09-26 | criteria provided, single submitter | clinical testing | Variant summary: EMD c.454C>T (p.Arg152Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico toos predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6e-05 in 183082 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in EMD causing Emery-Dreifuss Muscular Dystrophy (6e-05 vs 0.001), allowing no conclusion about variant significance. c.454C>T has been reported in the literature in individuals affected with cardiac myopathies, however, three publications classified the variant as VUS (example: Mook_2013, Paendonck-Zwarts_2014 and Verdonschot_2020). These reports do not provide unequivocal conclusions about association of the variant with Emery-Dreifuss Muscular Dystrophy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS(n=1) and likely benign (n=2). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Revvity Omics, |
RCV003491930 | SCV003833447 | uncertain significance | Emery-Dreifuss muscular dystrophy 1, X-linked | 2019-12-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005328223 | SCV005991189 | uncertain significance | Cardiovascular phenotype | 2025-01-25 | criteria provided, single submitter | clinical testing | The p.R152C variant (also known as c.454C>T), located in coding exon 6 of the EMD gene, results from a C to T substitution at nucleotide position 454. The arginine at codon 152 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant was reported in individual(s) with features consistent with dilated and hypertrophic cardiomyopathy (van Spaendonck-Zwarts KY et al. Eur J Heart Fail, 2013 Jun;15:628-36; Mook OR et al. J Med Genet, 2013 Sep;50:614-26; van Lint FHM et al. Neth Heart J, 2019 Jun;27:304-309). Based on data from gnomAD, the T allele has an overall frequency of 0.006% (11/183082) total alleles studied, with 3 hemizygote(s) observed. The highest observed frequency was 0.011% (9/81667) of European (non-Finnish) alleles. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Diagnostic Laboratory, |
RCV000616618 | SCV000734765 | uncertain significance | X-linked Emery-Dreifuss muscular dystrophy | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV000179255 | SCV001923533 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000179255 | SCV001928924 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000179255 | SCV001952098 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000179255 | SCV001973556 | uncertain significance | not provided | no assertion criteria provided | clinical testing |